department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

TG THERAPEUTICS, INC. ($TGTX) · pharmadog

PUBLIC COMPANY

$TGTXTG THERAPEUTICS, INC.

New York, NY, USupdated 2h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

3

marketed

1

phase 3

0

catalysts ytd

2

approvals ytd

1

recalls ytd

0

Pipeline(3)

pipeline depth3 products

1Marketed2Unknown

Relapsing Multiple Sclerosis (RMS)

1 INDICATIONS AND USAGE BRIUMVI is indicated for the trea…

B-lymphocyte antigen CD20

LEROCHOL

1 INDICATIONS AND USAGE LEROCHOL TM is indicated as an ad…

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

TG THERAPEUTICS, INC. earnings

TG THERAPEUTICS, INC.

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view TG THERAPEUTICS, INC. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$TGTX

SEC CIK

0001001316

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

Data sources

SEC EDGAR · openFDA

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$TGTX55.25+3.64%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase3An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosisactive not recruitingn=1,100
—A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)recruitingn=2,000
phase3Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximabrecruitingn=800
phase3Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosisnot yet recruitingn=240
phase1A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disordersrecruitingn=32
—A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milkrecruitingn=16
—A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)recruitingn=728
phase3A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)recruitingn=360

more trials →

Insider activity

source: SEC Form 4

routine RSU / option mechanics (2)

Jan 29, 26giftCharney Laurence N · director13,197 sh
Jan 28, 26giftCharney Laurence N · director30,000 sh

$TGTX55.25+3.64%

🐶 often sniffed alongside

top 3

tagApproval10 co-mentions · 5 sources
drugBRIUMVI10 co-mentions · 5 sources
drugublituximab10 co-mentions · 5 sources